Related Experiment Video
Updated: Feb 12, 2026

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
Published on: June 16, 2023
Knockdown of long non-coding RNA HOXD-AS1 inhibits the progression of osteosarcoma
Yang Qu1, Shuang Zheng1, Mingyang Kang1
1Department of Orthopaedics, the Second Hospital of Jilin University, #218 Ziqiang Street, Changchun 130041, China.
Abstract:
Long non-coding RNA HOXD-AS1 (HOXD-AS1) has recently been shown to be involved in the development and progression of multiple cancers. However, the expression, significance, and biological function of HOXD-AS1 in osteosarcoma (OS) remain unknown. Here, we found that the expression level of HOXD-AS1 was significantly upregulated in OS tissues and cells. Furthermore, high expression of HOXD-AS1 was positively associated with the clinical and pathological characteristics of OS, including tumor stage and lymph node metastasis, and negatively correlated with overall survival rate. in vitro assays confirmed that knockdown of HOXD-AS1 suppressed cell proliferation, colony formation, migration, and invasion, and promoted cell cycle arrest at G1 stage and apoptosis in OS cells. in vivo assays confirmed that knockdown of HOXD-AS1 significantly decreased tumor growth in xenograft mice, and decreased tumor size and weight. Importantly, we also showed that knockdown of HOXD-AS1 significantly reduced signal transducer and activator of transcription 3 and its target protein (CyclinD1, Bcl-2, and MMP-2) expression in vitro and in vivo. Moreover, overexpression of STAT3 could reverse the suppression of proliferation ability induced by sh-HOXD-AS1 in U2OS cells. Collectively, our data indicated that HOXD-AS1 might be an oncogenic long non-coding RNA (lncRNA) and might be a potential attractive therapeutic target for OS.
Insights
Long non-coding RNA HOXD-AS1 is upregulated in osteosarcoma, promoting cancer progression and poor survival. Silencing HOXD-AS1 inhibits tumor growth and metastasis by affecting the STAT3 pathway, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) play crucial roles in various cancers.
- The role of HOXD-AS1 in osteosarcoma (OS) development and progression is currently unknown.
Purpose of the Study:
- To investigate the expression, significance, and biological function of HOXD-AS1 in osteosarcoma.
- To explore the potential of HOXD-AS1 as a therapeutic target for OS.
Main Methods:
- Quantitative real-time PCR to assess HOXD-AS1 expression in OS tissues and cells.
- In vitro assays (proliferation, colony formation, migration, invasion, cell cycle, apoptosis) to evaluate the function of HOXD-AS1.
- In vivo xenograft mouse models to assess tumor growth.
- Western blotting to analyze protein expression (STAT3 and its targets).
Main Results:
- HOXD-AS1 expression was significantly upregulated in OS tissues and cells.
- High HOXD-AS1 expression correlated with advanced tumor stage, lymph node metastasis, and reduced overall survival.
- Knockdown of HOXD-AS1 suppressed OS cell proliferation, migration, invasion, and tumor growth, while promoting apoptosis and G1 cell cycle arrest.
- HOXD-AS1 knockdown reduced STAT3 and its target protein expression (CyclinD1, Bcl-2, MMP-2).
- STAT3 overexpression reversed the inhibitory effects of HOXD-AS1 knockdown on proliferation.
Conclusions:
- HOXD-AS1 acts as an oncogenic lncRNA in osteosarcoma.
- HOXD-AS1 promotes OS progression through the STAT3 signaling pathway.
- HOXD-AS1 represents a potential therapeutic target for osteosarcoma treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Feedback Inhibition
RNA Splicing
Ribosomal RNA Synthesis
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Nursing Code of Ethics

